APY0201

Description	APY0201 works differently from anti-IL-12/23 antibodies and acts by inhibiting production of these proinflammatory cytokines with characteristic selectivity over other cytokines, including tumor necrosis factor-alpha (TNF-α). In stimulated thioglycollate-induced mouse peritoneal exudate cells (TG-PEC), APY0201 strongly inhibited IL-12p70 and IL-12p40 production, with IC50 values of 8.4 and 16 nM, respectively. APY0201 also inhibited IL-12p40 at 99 nM in human PBMC. APY0201 showed significant selectivity for the production of IL-12p70 and IL-12p40 over TNF-α, and this selectivity was maintained across species. in vivo: Oral APY0201 at a 30 mg/kg dose showed significant reduction of IL-12p70 production (78% inhibition relative to that of the vehicle control), which implied that the inhibitory potential of APY0201 against IL-12 was confirmed in the animal experiment.
Pathways	Others Pathway
Targets	Interleukin Related

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.